has seen a lackluster launch. However, Biogen CEO Chris Viehbacher said on Tuesday that there are a “number of catalysts” that could accelerate Leqembi’s growth in 2025. Since its approval ...

Bristol Myers Squibb has turned to the source of Leqembi to further its push into ... the brain making it possible to reach deeper brain structures. A fast blood-brain barrier transport results ...